Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20916888 | 0.78 | CYP17A1 (0.33) | CYP17A1CYP21A2CYP11B1CHRNB4CHRNA3 | |
| SCHEMBL30402940 | 0.76 | ALDH1A1 (0.33) | CYP17A1CYP21A2CYP11B1CHRNB4CHRNA3 | |
| SCHEMBL28364086 | 0.76 | CYP17A1 (0.33) | CYP17A1CYP21A2CYP11B1CHRNB4CHRNA3 | |
| SCHEMBL27827613 | 0.76 | PTGS1 (0.33) | CYP17A1CYP21A2CYP11B1CHRNB4CHRNA3 | |
| SCHEMBL613761 | 0.76 | ALDH1A1 (0.46) | CYP17A1CYP21A2CYP11B1CHRNB4CHRNA3 | |
| SCHEMBL16960316 | 0.76 | PTGS1 (0.33) | CYP17A1CYP21A2CYP11B1CHRNB4CHRNA3 | |
| SCHEMBL30374708 | 0.76 | ALDH1A1 (0.46) | CYP17A1CYP21A2CYP11B1CHRNB4CHRNA3 | |
| SCHEMBL5224160 | 0.76 | CYP17A1 (0.33) | CYP17A1CYP21A2CYP11B1CHRNB4CHRNA3 | |
| SCHEMBL5781705 | 0.76 | ALDH1A1 (0.33) | CYP17A1CYP21A2CYP11B1CHRNB4CHRNA3 | |
| SCHEMBL16680422 | 0.74 | ALDH1A1 (0.35) | CYP17A1CYP21A2CYP11B1CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10676477-B2 | Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676477-B2 | Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group | TFPI, TFPI2, F2 | CYP17A1 665/4885CYP21A2 819/4885CYP11B1 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.